172 related articles for article (PubMed ID: 37660406)
1. Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy.
Hu YJ; Lu TZ; Zhang H; Fang M; Chen BJ; Guo QJ; Lin SJ; Feng P; Wang Y; Jiang TC; Gong XC; Pan JJ; Li JG; Xia YF
ESMO Open; 2023 Oct; 8(5):101629. PubMed ID: 37660406
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
3. Subdivision of de-novo metastatic nasopharyngeal carcinoma based on tumor burden and pretreatment EBV DNA for therapeutic guidance of locoregional radiotherapy.
Yang JH; Sun XS; Xiao BB; Liu LT; Guo SS; Liang JD; Jia GD; Tang LQ; Chen QY; Mai HQ
BMC Cancer; 2021 May; 21(1):534. PubMed ID: 33975558
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy.
Chen Y; Chen C; Peng H; Lin S; Pan J; Zheng H; Zong J; Lin C
Sci Rep; 2024 Feb; 14(1):3950. PubMed ID: 38366057
[TBL] [Abstract][Full Text] [Related]
5. Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis.
Yao Y; Sun X; Huang H; Wang Z; Fang X; Chen M; Chen Z; Weng H; Guo C; Hong H; Huang H; Lin T
Radiat Oncol; 2023 Jan; 18(1):15. PubMed ID: 36681832
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the treatment mode for de novo metastatic nasopharyngeal carcinoma with bone-only metastasis.
Lin C; Lin S; Zhu L; Lin S; Pan J; Xu Y
BMC Cancer; 2022 Jan; 22(1):35. PubMed ID: 34983459
[TBL] [Abstract][Full Text] [Related]
7. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance.
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
Cancer Res Treat; 2019 Oct; 51(4):1259-1268. PubMed ID: 30653745
[TBL] [Abstract][Full Text] [Related]
8. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study.
Sun XS; Liu SL; Liang YJ; Chen QY; Li XY; Tang LQ; Mai HQ
Cancer Commun (Lond); 2020 Jan; 40(1):32-42. PubMed ID: 32112522
[TBL] [Abstract][Full Text] [Related]
9. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
[TBL] [Abstract][Full Text] [Related]
10. Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy.
Li WZ; Hua X; Xie DH; Liang H; Liu GY; Xia WX; Xiang YQ
ESMO Open; 2021 Feb; 6(1):100004. PubMed ID: 33399071
[TBL] [Abstract][Full Text] [Related]
11. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
[TBL] [Abstract][Full Text] [Related]
12. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
13. Effects of locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A real-world study.
Zeng F; Lu T; Xie F; Chen L; Zhang L; Su Y; Yu Z; Xiao Y; Ao F; Li G; Chen Z; Gong X; Li J
Transl Oncol; 2021 Nov; 14(11):101187. PubMed ID: 34365221
[TBL] [Abstract][Full Text] [Related]
14. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
15. Effective of metastasis-directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis.
Liu GY; Li Z; Chen XX; Xia WX; Yao HR; Xiang YQ
Head Neck; 2023 Oct; 45(10):2571-2579. PubMed ID: 37554098
[TBL] [Abstract][Full Text] [Related]
16. Identifying the optimal candidates for locoregional radiation therapy in patients with de novo metastatic nasopharyngeal carcinoma.
Xu H; Lu L; Lu T; Xu Y; Zong J; Huang C; Lin F; Zheng Y; Lin C; Lin S; Qiu S; Pan J; Lin S; Guo Q
Head Neck; 2021 Sep; 43(9):2602-2610. PubMed ID: 33904617
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
19. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
20. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
[Next] [New Search]